These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 14585937

  • 1. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
    Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators.
    N Engl J Med; 2003 Oct 30; 349(18):1695-702. PubMed ID: 14585937
    [Abstract] [Full Text] [Related]

  • 2. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV, CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.
    N Engl J Med; 2001 Mar 01; 344(9):626-31. PubMed ID: 11228276
    [Abstract] [Full Text] [Related]

  • 3. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P, Carnovali M, Marchiori A, Galilei Investigators.
    Arch Intern Med; 2004 May 24; 164(10):1077-83. PubMed ID: 15159264
    [Abstract] [Full Text] [Related]

  • 4. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR.
    Thromb Haemost; 2009 Apr 24; 101(4):762-9. PubMed ID: 19350123
    [Abstract] [Full Text] [Related]

  • 5. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH.
    N Engl J Med; 1996 Mar 14; 334(11):682-7. PubMed ID: 8594426
    [Abstract] [Full Text] [Related]

  • 6. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
    Bauer KA, Eriksson BI, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Major Knee Surgery Study.
    N Engl J Med; 2001 Nov 01; 345(18):1305-10. PubMed ID: 11794149
    [Abstract] [Full Text] [Related]

  • 7. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G.
    N Engl J Med; 1998 Feb 12; 338(7):409-15. PubMed ID: 9459643
    [Abstract] [Full Text] [Related]

  • 8. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
    Eriksson BI, Bauer KA, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study.
    N Engl J Med; 2001 Nov 01; 345(18):1298-304. PubMed ID: 11794148
    [Abstract] [Full Text] [Related]

  • 9. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJ, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KA, Yusuf S, ASPIRE Investigators.
    Circulation; 2005 Mar 22; 111(11):1390-7. PubMed ID: 15781750
    [Abstract] [Full Text] [Related]

  • 10. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F.
    N Engl J Med; 1997 Aug 14; 337(7):447-52. PubMed ID: 9250846
    [Abstract] [Full Text] [Related]

  • 11. Idraparinux versus standard therapy for venous thromboembolic disease.
    van Gogh InvestigatorsAcademic Medical Center, Department of Vascular Medicine, F4-211, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. h.r.buller@amc.uva.nl, Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE.
    N Engl J Med; 2007 Sep 13; 357(11):1094-104. PubMed ID: 17855670
    [Abstract] [Full Text] [Related]

  • 12. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jolly S, Granger CB, Fox KA, Bassand JP, Yusuf S, OASIS 5 and 6 Investigators.
    Circulation; 2008 Nov 11; 118(20):2038-46. PubMed ID: 18955665
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
    Eriksson BI, Lassen MR, PENTasaccharide in HIp-FRActure Surgery Plus Investigators.
    Arch Intern Med; 2003 Jun 09; 163(11):1337-42. PubMed ID: 12796070
    [Abstract] [Full Text] [Related]

  • 16. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
    Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR.
    N Engl J Med; 1992 Apr 09; 326(15):975-82. PubMed ID: 1545850
    [Abstract] [Full Text] [Related]

  • 17. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF, Neuhart E.
    Thromb Haemost; 1996 Oct 09; 76(4):529-34. PubMed ID: 8902991
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators.
    N Engl J Med; 2003 Jul 10; 349(2):146-53. PubMed ID: 12853587
    [Abstract] [Full Text] [Related]

  • 20. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M.
    N Engl J Med; 1996 Mar 14; 334(11):677-81. PubMed ID: 8594425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.